News List

Wednesday February 18, 2009 2008 annual revenue over expectations, at €4.1m (+62.4%)

Strong sales growth, markedly in the United States: +208.2%

Category: Investors

Monday February 02, 2009 Next Events and Congresses (S1 2009)

Ipsogen is participating to a great number of international congresses. Ipsogen’s team will be happy to meet you and discuss your current needs and find out about Ipsogen’s latest developments.In the Life Science Business...

Category: Corporate

Monday January 26, 2009 Ipsogen appoints Hélène Peyro-Saint-Paul as Chief Medical Officer

Marseille, France, January 26, 2009 - IPSOGEN SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, production and commercialization of diagnostic assays for breast cancer and...

Category: Corporate

Monday January 12, 2009 In 2008, Ipsogen reinforced its leadership in molecular diagnosis and monitoring of leukemia

During the last quarter of 2008, Ipsogen launched three new molecular diagnostic kits

Category: Leukemia

Sunday November 23, 2008 Ipsogen launches a new test to determine tumor HER2 status and guide Herceptin® prescription in breast cancer

Ipsogen’s HER2 test further strengthens the rapidly expanding MapQuant Dx™ platform, a microarray-based comprehensive solution designed to guide therapy decisions in breast cancer.

Category: Breast Cancer

Thursday October 09, 2008 2008 Half-Year Results

Results in line with expectations.

A first half-year marked by important advances.

Category: Investors

Saturday October 04, 2008 Ipsogen expands its U.S. market presence through licensing agreement with Quest Diagnostics

Marseille, France, October 6th, 2008

Ipsogen SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and...

Category: Leukemia, Investors

Wednesday September 24, 2008 Liquidity agreement

Luminy, 22 September 2008 – IPSOGEN (Alternext - FR0010626028 - ALIPS), a pioneer and key player in the development and commercialization of molecular diagnostic tests for cancer, today announces the terms of its liquidity...

Category: Investors

Tuesday September 02, 2008 Ipsogen S.A consolidates its position in North America and appoints Susan Hertzberg President, Ipsogen Inc

Susan’s  broad commercial experience and deep knowledge of the IVD and laboratory services sectors is a great advantage to expand Ipsogen’s presence in North America and around the world.Marseille, France, September 1st,...

Category: Corporate, Investors

Monday September 01, 2008 Ipsogen expands its sales force

After the success of its recent IPO, Ipsogen is committed to strengthen its commercial operations worldwide. In this perspective, Ipsogen recently started a targeted recruitment campaign. By joining Ipsogen, you will actively...

Category: Corporate